Table 1 Patient characteristics

Sex (female)

58 (43.3%)

18 (40.0%)

0.731^a)

Age (year)

69 (33–85)

66 (32–82)

0.345^b)

Body surface area (m²)

1.570 (1.192–2.010)

1.583 (1.223–1.941)

0.717^b)

BMI (kg/m²)

21.9 (15.0–36.5)

21.6 (15.9–33.8)

0.958^b)

Primary rectal tumor

44 (32.8%)

17 (31.1%)

0.588

Number of metastases (n)

1 (1–5)

1 (1–3)

0.589^b)

Types of molecular-targeted drugs

Bevacizumab: 134 (100%)

Panitumumab: 40 (88.9%)

-

Cetuximab: 5 (11.1%)

Number of cytotoxic anticancer drugs used in combination (3/2/1)

5/120/9

0/45/0

0.075^a)

Number of first-line treatments (n)

10.5 (1–62)

9 (1–40)

0.454^b)

CV port construction, yes (n)

110 (82.1%)

45 (100%)

 < 0.001^a)

Comorbid cardiac disease (n)

2 (1.5%)

3 (6.7%)

0.601^a)

Comorbid hypertension (n)

35 (26.1%)

16 (35.6%)

0.254^a)

Comorbid diabetes mellitus (n)

17 (12.7%)

5 (11.1%)

1.000^a)

Concomitant use of hormonal agents (n)

0 (0.0%)

0 (0.0%)

-

Concomitant use of hematopoietic agents (n)

0 (0.0%)

0 (0.0%)

-

WBC count before starting treatment (× 10³/μL)

5.55 (2.3–14.4)

5.90 (3.0–11.6)

0.164^b)

Platelet count before starting treatment (× 10³/μL)

230.5 (79–693)

246 (114–454)

0.423^b)

Hemoglobin level before starting treatment (g/dL)

11.6 (7.9–15.7)

11.6 (6.5–16.4)

0.552^b)

Number of risk factors (0/1/2/3)

84/41/7/2

25/15/5/0

0.438^a)

Median number of days from treatment start date to thromboembolism onset date

84.5 (18–200)

101 (7–707)

0.678^b)